SCHEMBL1497033

SCHEMBL1497033

CN(C)CCC(NC(=O)NCc1cccc(F)c1)c1ccc(C(=O)Nc2cscc2NC(=O)OC(C)(C)C)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 4/20 0.44
OPRM1 P35372 2/20 0.37
OPRL1 P41146 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
CDK9 P50750 1/20 0.36
ANPEP P15144 1/20 0.35
CCNT1 O60563 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35
ALDH1A1 P00352 2/20 0.35
TSHR P16473 2/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.34
RET P07949 1/20 0.34
HSD17B13 Q7Z5P4 1/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1497075 0.91 UTS2R (0.44) UTS2RTSHRMAPK1HDAC1
SCHEMBL1496907 0.91 UTS2R (0.45) UTS2RANPEPATG4BROCK2ROCK1
SCHEMBL1496837 0.89 UTS2R (0.46) UTS2ROPRM1ROCK2ROCK1
SCHEMBL1496976 0.88 UTS2R (0.45) UTS2RALDH1A1TSHRHDAC1
SCHEMBL1496897 0.88 UTS2R (0.47) UTS2ROPRM1OPRL1ANPEPATG4B
SCHEMBL1497113 0.88 UTS2R (0.45) UTS2RROCK2HDAC1
SCHEMBL1497003 0.86 UTS2R (0.44) UTS2RALDH1A1POLB
SCHEMBL10476443 0.86 UTS2R (0.38) UTS2RPOLB
SCHEMBL1496965 0.86 UTS2R (0.39) UTS2RROCK2ROCK1
SCHEMBL1496865 0.85 UTS2R (0.36) UTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 US disclosed
EP-2292611-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2011-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE CBR1, NAT1, PRMT1 UTS2R 195/4885OPRM1 78/4885OPRL1 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.